## Edgar Filing: SMITH IAN F - Form 4/A

CNAUTTI LAND

Form 4/A	F										
December 21	. 2005										
								OMB APPROVAL			
		TIES AND EXCHANGE COMMISSION ington, D.C. 20549					3235-0287				
Check the if no long	ter.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							Expires: Janu	January 31, 2005	
subject to Section 1 Form 4 o Form 5	6. r								Estimated average burden hours per response 0.		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type F	Responses)										
1. Name and A SMITH IAN	2. Issuer Name <b>and</b> Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) C/O VERTH PHARMAC	3. Date of Earliest Transaction (Month/Day/Year) 12/16/2005					Director 10% Owner X_Officer (give title Other (specify below) below) SVP & CFO					
INCORPOR STREET	RATED, 130 W.	AVERLY									
File				endment, Da nth/Day/Year 005	-	l		<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting Person</li> </ul>			
(City)	(State)	(Zip)	Tabl	le I - Non-D	erivative	Securi	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year		n Date, if	3. Transactio Code (Instr. 8)	4. Securit n(A) or Dia (Instr. 3, 4	sposed	l of (D)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Common Stock	12/21/2005(1)			S	11,811	D	\$ 27.88	70,250	D		
Common Stock								3,927	Ι	401(k)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

### Edgar Filing: SMITH IAN F - Form 4/A

#### number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Conversion (Month/Day/Year) Execution or Exercise any Price of (Month/Da Derivative		4. Transactio Code (Instr. 8)	5. orNumber of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration (Month/Day ve ss 1			tle and unt of erlying rities r. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration e Date	Title	Amount or Number of Shares		
Reporting Owners											
	Repor	ting Owner Name / A	Adress	D.		Relation					
SMITH L	AN F			Dire	rector 10	)% Owner	Officer	C	Other		

C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE, MA 02139

SVP & CFO

# Signatures

Valerie L. Andrews, Attorney-In-Fact 12/21/2005

\*\*Signature of Reporting Person

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

(1) This Form 4 amends the Form 4 filed on behalf of Mr. Smith on December 20, 2005 to reflect a different transaction date and price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.